Literature DB >> 23323898

Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy.

Tuan Le1, Edwina J Wright, Davey M Smith, Weijing He, Gabriel Catano, Jason F Okulicz, Jason A Young, Robert A Clark, Douglas D Richman, Susan J Little, Sunil K Ahuja.   

Abstract

BACKGROUND: The relationship between the timing of the initiation of antiretroviral therapy (ART) after infection with human immunodeficiency virus type 1 (HIV-1) and the recovery of CD4+ T-cell counts is unknown.
METHODS: In a prospective, observational cohort of persons with acute or early HIV-1 infection, we determined the trajectory of CD4+ counts over a 48-month period in partially overlapping study sets: study set 1 included 384 participants during the time window in which they were not receiving ART and study set 2 included 213 participants who received ART soon after study entry or sometime thereafter and had a suppressed plasma HIV viral load. We investigated the likelihood and rate of CD4+ T-cell recovery to 900 or more cells per cubic millimeter within 48 months while the participants were receiving viral-load-suppressive ART.
RESULTS: Among the participants who were not receiving ART, CD4+ counts increased spontaneously, soon after HIV-1 infection, from the level at study entry (median, 495 cells per cubic millimeter; interquartile range, 383 to 622), reached a peak value (median, 763 cells per cubic millimeter; interquartile range, 573 to 987) within approximately 4 months after the estimated date of infection, and declined progressively thereafter. Recovery of CD4+ counts to 900 or more cells per cubic millimeter was seen in approximately 64% of the participants who initiated ART earlier (≤4 months after the estimated date of HIV infection) as compared with approximately 34% of participants who initiated ART later (>4 months) (P<0.001). After adjustment for whether ART was initiated when the CD4+ count was 500 or more cells per cubic millimeter or less than 500 cells per cubic millimeter, the likelihood that the count would increase to 900 or more cells per cubic millimeter was lower by 65% (odds ratio, 0.35), and the rate of recovery was slower by 56% (rate ratio, 0.44), if ART was initiated later rather than earlier. There was no association between the plasma HIV RNA level at the time of initiation of ART and CD4+ T-cell recovery.
CONCLUSIONS: A transient, spontaneous restoration of CD4+ T-cell counts occurs in the 4-month time window after HIV-1 infection. Initiation of ART during this period is associated with an enhanced likelihood of recovery of CD4+ counts. (Funded by the National Institute of Allergy and Infectious Diseases and others.).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23323898      PMCID: PMC3657555          DOI: 10.1056/NEJMoa1110187

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  29 in total

Review 1.  HIV and inflammation: mechanisms and consequences.

Authors:  Peter W Hunt
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

2.  CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4+ T cells.

Authors:  Sonia Fernandez; Sara Tanaskovic; Karla Helbig; Reena Rajasuriar; Marit Kramski; John M Murray; Michael Beard; Damian Purcell; Sharon R Lewin; Patricia Price; Martyn A French
Journal:  J Infect Dis       Date:  2011-10-17       Impact factor: 5.226

3.  Immunological changes in primary HIV-1 infection.

Authors:  H Gaines; M A von Sydow; L V von Stedingk; G Biberfeld; B Böttiger; L O Hansson; P Lundbergh; A B Sönnerborg; J Wasserman; O O Strannegåard
Journal:  AIDS       Date:  1990-10       Impact factor: 4.177

4.  Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites.

Authors:  W H Belloso; L C Orellana; B Grinsztejn; J S Madero; A La Rosa; V G Veloso; J Sanchez; R Ismerio Moreira; B Crabtree-Ramirez; O Garcia Messina; M B Lasala; J Peinado; M H Losso
Journal:  HIV Med       Date:  2010-03-21       Impact factor: 3.180

5.  Characterization of T lymphocyte responses during primary infection with human immunodeficiency virus.

Authors:  D A Cooper; B Tindall; E J Wilson; A A Imrie; R Penny
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

6.  Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines.

Authors:  Sara Lodi; Andrew Phillips; Giota Touloumi; Ronald Geskus; Laurence Meyer; Rodolphe Thiébaut; Nikos Pantazis; Julia Del Amo; Anne M Johnson; Abdel Babiker; Kholoud Porter
Journal:  Clin Infect Dis       Date:  2011-10       Impact factor: 9.079

7.  Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.

Authors:  Melanie A Thompson; Judith A Aberg; Pedro Cahn; Julio S G Montaner; Giuliano Rizzardini; Amalio Telenti; José M Gatell; Huldrych F Günthard; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; Peter Reiss; Douglas D Richman; Paul A Volberding; Patrick Yeni; Robert T Schooley
Journal:  JAMA       Date:  2010-07-21       Impact factor: 56.272

Review 8.  A review on peripheral blood CD4+ T lymphocyte counts in healthy adult Indians.

Authors:  Ashwini Shete; Madhuri Thakar; Philip Raj Abraham; Ramesh Paranjape
Journal:  Indian J Med Res       Date:  2010-12       Impact factor: 2.375

9.  Lymphoid tissue damage in HIV-1 infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy.

Authors:  Ming Zeng; Peter J Southern; Cavan S Reilly; Greg J Beilman; Jeffrey G Chipman; Timothy W Schacker; Ashley T Haase
Journal:  PLoS Pathog       Date:  2012-01-05       Impact factor: 6.823

10.  Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection.

Authors:  Jintanat Ananworanich; Alexandra Schuetz; Claire Vandergeeten; Irini Sereti; Mark de Souza; Rungsun Rerknimitr; Robin Dewar; Mary Marovich; Frits van Griensven; Rafick Sekaly; Suteeraporn Pinyakorn; Nittaya Phanuphak; Rapee Trichavaroj; Wiriya Rutvisuttinunt; Nitiya Chomchey; Robert Paris; Sheila Peel; Victor Valcour; Frank Maldarelli; Nicolas Chomont; Nelson Michael; Praphan Phanuphak; Jerome H Kim
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

View more
  192 in total

1.  Routine Screening for HIV Infection in Medical Care Settings: A Decade of Progress and Next Opportunities.

Authors:  Patrick S Sullivan; Michael S Lyons; Maggie Czarnogorski; Bernard M Branson
Journal:  Public Health Rep       Date:  2016 Jan-Feb       Impact factor: 2.792

Review 2.  Treatment of Acute HIV Infection and the Potential Role of Acutely HIV-Infected Persons in Cure Studies.

Authors:  Susan J Little
Journal:  Top Antivir Med       Date:  2016 Dec-2017 Jan

Review 3.  Antiretroviral therapy: when to start.

Authors:  Christopher J Sellers; David A Wohl
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

4.  HIV-1 and HIV-2 differentially mature plasmacytoid dendritic cells into IFN-producing cells or APCs.

Authors:  Caroline M Royle; David R Graham; Simone Sharma; Dietmar Fuchs; Adriano Boasso
Journal:  J Immunol       Date:  2014-08-25       Impact factor: 5.422

5.  Late presentation to HIV/AIDS testing, treatment or continued care: clarifying the use of CD4 evaluation in the consensus definition.

Authors:  S MacCarthy; D R Bangsberg; G Fink; M Reich; S Gruskin
Journal:  HIV Med       Date:  2013-09-11       Impact factor: 3.180

6.  Frailty, Inflammation, and Mortality Among Persons Aging With HIV Infection and Injection Drug Use.

Authors:  Damani A Piggott; Ravi Varadhan; Shruti H Mehta; Todd T Brown; Huifen Li; Jeremy D Walston; Sean X Leng; Gregory D Kirk
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2015-09-18       Impact factor: 6.053

7.  Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection.

Authors:  Murli U Purswani; Brad Karalius; Tzy-Jyun Yao; D Scott Schmid; Sandra K Burchett; George K Siberry; Kunjal Patel; Russell B Van Dyke; Ram Yogev; Robert H Lurie; Ram Yogev; Margaret Ann Sanders; Kathleen Malee; Scott Hunter; William Shearer; Mary Paul; Norma Cooper; Lynnette Harris; Murli Purswani; Mahboobullah Baig; Anna Cintron; Ana Puga; Sandra Navarro; Patricia Garvie; James Blood; Sandra Burchett; Nancy Karthas; Betsy Kammerer; Andrew Wiznia; Marlene Burey; Molly Nozyce; Arry Dieudonne; Linda Bettica; Susan Adubato; Janet Chen; Maria Garcia Bulkley; Latreaca Ivey; Mitzie Grant; Katherine Knapp; Kim Allison; Megan Wilkins; Midnela Acevedo-Flores; Heida Rios; Vivian Olivera; Margarita Silio; Medea Jones; Patricia Sirois; Stephen Spector; Kim Norris; Sharon Nichols; Elizabeth McFarland; Alisa Katai; Jennifer Dunn; Suzanne Paul; Gwendolyn Scott; Patricia Bryan; Elizabeth Willen
Journal:  Clin Infect Dis       Date:  2015-09-18       Impact factor: 9.079

8.  No Time to Delay! Fiebig Stages and Referral in Acute HIV infection: Seattle Primary Infection Program Experience.

Authors:  Joanne D Stekler; Kenneth Tapia; Janine Maenza; Claire E Stevens; George A Ure; Joshua D O'Neal; Aric Lane; James I Mullins; Robert W Coombs; Sarah Holte; Ann C Collier
Journal:  AIDS Res Hum Retroviruses       Date:  2018-06-13       Impact factor: 2.205

9.  Real-world performance of the new US HIV testing algorithm in medical settings.

Authors:  Kara G Marson; Robert Marlin; Phong Pham; Stephanie E Cohen; Diane Jones; Marguerite Roemer; Philip J Peters; Barbara Haller; Christopher D Pilcher
Journal:  J Clin Virol       Date:  2017-04-07       Impact factor: 3.168

10.  Concurrency and HIV transmission network characteristics among MSM with recent HIV infection.

Authors:  Heather A Pines; Joel O Wertheim; Lin Liu; Richard S Garfein; Susan J Little; Maile Y Karris
Journal:  AIDS       Date:  2016-11-28       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.